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eluting stent (DES) era.
Methods: We consecutively enrolled acute myocardial infarction (AMI) patients who
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnver-
gent REgistry of cAtholic and chonnAm university for AMI) from January 2004 to
December 2009. Of 4,748 AMI patients, 2,607 and 1,617 patients who treated with
only DES were diagnosed with STEMI and NSTEMI, respectively. The primary
endpoint is 30-day all-cause mortality and mortality from 31 days to 5 years. We
performed landmark analysis at 30 days.
Results:Median follow up duration was 43.3 months (interquartile range 29.4 to 59.7
months). All-cause mortality rate at 30 days was higher in STEMI (3.6%; 94 patients)
than NSTEMI (2.4%; 39 deaths; P¼0.031). On the other hand, mortality from 31 days
to 5 years was higher in NSTEMI (17.4% vs. 13.7%; 273 deaths vs. 343 deaths;
P¼0.001). After adjustment with clinical and angiographic characteristics, STEMI is
associated with 30-day mortality (hazard ratio (HR) 1.54, 95% conﬁdence interval
(CI) 1.06-2.25, P¼0.025) and NSTEMI is independent predictor for mortality from 31
days to 5 years (HR 1.26, 95% CI 1.07-1.48, P¼0.006).Conclusions: STEMI was associated with a higher risk of short-term mortality, but
NSTEMI was associated with a higher risk of long-term mortality in the DES era.
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Background: While clinical outcomes undoubtedly favor primary percutaneous
coronary intervention (PPCI) over thrombolysis for ST-elevation Myocardial Infarc-
tion (STEMI), there is paucity of data on the optimal length of hospital stay.
Methods: Between Jan. 2008 and Sep. 2009, a total of 4,549 STEMI patients enrolled
in the Korea Acute Myocardial Infarction Registry(KAMIR) who underwent PPCI
and survived to hospital discharge, were grouped according to the length of stay in
hospital: Group I (short stay, 3 day, n¼809); Group II (medium stay, 4-6 days,
n¼2,263); Group III (long stay, 7 days, n¼1,477). We investigated major adverse
cardiac events (MACEs) at 1, 6, and 12 months and independent predictors of long
stay in hospital.
Results: Group III were signiﬁcant older age (62.8 vs. 63.3 vs. 66.9 years, p< 0.001),
more female (18.3, 22.3, 30.2%, p< 0.001), lower body mass index (BMI) (24.8, 24.2,
23.7, p¼0.001), higher Killip classII (19.9, 26.1, 41.3%, p< 0.001), higher three
vessel disease (14.4, 16.8, 19.6%, p¼0.005), higher prevalence of complication during
PPCI (4.1, 7.7, 18.5%, p< 0.001); higher level of NT-proBNP, lower LV ejection
fraction(EF) (p< 0.001). There were no signiﬁcant difference of MACE at 1, 12
months between Group I, II and III (1 month MACE: 2.4 vs. 1.7 vs. 2.3%, p¼0.475;
12 months: 3.4, 5.6, 3.9%, p¼0.262). In multivariate analysis, independent predictors
of long stay (7 days) in hospital were advanced Killip class II (odds ratio [OR]
1.752; 95% CI, 1.361-2.255, p< 0.001), higher complication rates during PPCI (OR
2.479; 95% CI, 1.737-3.537, p< 0.001), EF < 35% (OR 1.853; 95% CI, 1.142-3.007,
p¼0.013), creatinine > 2.5 mg/dL (OR 3.900; 95% CI, 1.053-14.441, p¼0.042),
higher troponin I (OR 1.698; 95% CI, 1.353-2.132, p< 0.001) and NT-pro BNP
levels(OR 1.946; 95% CI, 1.468-2.580, p< 0.001).
Conclusions: Short length of stay in hospital for low-risk and uncomplicated patients
was similar clinical outcomes and prognosis compared with medium, long stay after
PPCI for STEMI during a 12-month clinical follow-up.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-36
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Background: We evaluated the impact of normal versus high presenting BP on
clinical outcomes and cardiac function in patients with acute ST-elevation myocar-
dial infarction (STEMI) treated with primary percutaneous coronary intervention
(PPCI).
Methods: A total of 12,234 STEMI patients treated with primary percutaneous
coronary intervention (PPCI) were compared according to normal (systolic BP
>90 mmHg and 139 mmHg) versus high (systolic BP 140 mmHg) presenting
BP.
Results: Patients with normal presenting BP (n ¼ 7,647, 62.5%) were associated with
signiﬁcantly higher in-hospital mortality (4.3 vs. 1.8%, p < 0.001), particularly in
patients with prior hypertension, when compared to patients with high presenting
BP (n ¼ 4,587, 37.5%). Patients with normal presenting BP showed higher incidence
of cardiac death (5 vs. 2.6%, p < 0.001) and the composite of major adverse
cardiac events (MACE, deﬁned as all-cause death, myocardial infarction, or re-
vascularizations; 12.2 vs. 10.1%, p < 0.001) at one-year when compared to patients
with high presenting BP. Left ventricular ejection fraction was signiﬁcantly lower in
patients with normal presenting BP at baseline and follow-up (50.7 vs. 51.9%, p <
0.001; 53.6 vs. 54.7%, p ¼ 0.011, respectively). Normal presenting BP was associated
with increased risk of in-hospital mortality (adjusted OR 2.472, CI 1.681-3.635, p <
0.001) in logistic regression analysis. However, it was not associated with cardiac
death (adjusted HR 1.02, CI 0.671-1.55, p¼0.927) and the composite of MACE
(adjusted HR 0.887, CI 0.693-1.135, p ¼ 0.34) at one-year in Cox proportional hazard
regression analysis.
Conclusions: Normal presenting BP, particularly in patients with prior hyper-
tension, was associated with increased in-hospital mortality and lower cardiac
function in STEMI patients treated with PPCI when compared to high presenting
BP. However, outcomes were not different in both groups of patients at one-year
although cardiac function was persistently lower in patients with normal pre-
senting BP.
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Background:We compared the efﬁcacy and safety of sirolimus-eluting stents (SESs),
everolimus-eluting stents (EESs), biodegradable polymer stent (BP-DESs), and
endothelial progenitor cell capture stents (EPCCSs).
Methods: From the IRIS-DES registry, we identiﬁed 1517 patients treated using PCI
with SESs (N ¼ 372), EESs (N ¼ 405), BP-DESs (N ¼ 300), and EPCCSs (N¼440)
in ST-elevation myocardial infarction (STEMI). Major adverse cardiac events
(MACE) were deﬁned using composite of death, myocardial infarction, and target
vessel revasularization at 24 months.
Results: At 2 years, there was no difference in the incidence of MACE (8.5% in
SESs, 9.9% in EES, 10.2% in BP-DES, and 12.8% in EPCCS, P ¼ 0.281), death
(5.0% in SESs, 4.3% in EES, 4.4% in BP-DES, and 6.2% in EPCCS, P ¼ 0.718),
MI (0.6% in SESs, 1.6% in EES, 1.5% in BP-DES, and 1.5% in EPCCS, P ¼
0.572), and TVR (3.8% in SESs, 5.9% in EES, 4.8% in BP-DES, and 6.5% in
EPCCS, P ¼ 0.313). The EPCCSs group showed trend of higher rate in any
revascularization, but no signiﬁcantly statistical difference (6.6% in SESs, 9.1% in
EES, 7.2% in BP-DES, and 11.6% in EPCCS, P ¼ 0.313). The cumulative rates of
deﬁnite stent thrombosis were 0.3% in SESs, 1.2% in EESs, 0.7% in BP-DESs, and
1.6% in EPCCSs (P ¼ 0.239).
Conclusions: The 4 different DESs showed no signiﬁcant difference in clinical
outcome at 2-year follow-up in patients with STEMI.ute Myocardial Infarction B11
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Background: XIENCE V USA is a prospective, multicenter, single-arm, FDA con-
dition- of-approval study to evaluate the safety and effectiveness of the XIENCE V
Everolimus Eluting Stent (XIENCE V, Abbott Vascular, Santa Clara, CA) in a real-
world, all-comer population. Clinical outcomes at 1 year in AMI patients have been
previously reported with low rates of target lesion revascularization (TLR), cardiac
death, MI and stent thrombosis (ST). Whether these early results from XIENCE V
USA in AMI are sustained long term has not been reported.
Methods: This study consecutively enrolled 5054 patients undergoing PCI with
XIENCE V only from July to December 2008. A total of 4176 patients who completed
4 year clinical follow up or experienced endpoint events were included in this anal-
ysis. Clinical outcomes in patients with (n¼667, 125 patients with STEMI) and
without (n¼3509) AMI were compared up to 4 years.
Results: Mean age, gender distribution, lesion length, and number of lesions and
vessels treated were similar across the two groups. The AMI group had a fewer di-
abetics, lower rates of dyslipidemia, hypertension, but higher rates of tobacco use,
unstable angina, prior MI, B2/C lesions, compared to the non-AMI group. Clinical






(L ¼ 4918) P-value
Cardiac Death 6.3% 4.9% 0.1585
MI (WHO deﬁnition) 6.9% 4.4% 0.0093
Q-MI 3.5% 1.2% 0.0003
NQMI 3.9% 3.2% 0.3208
Target Lesion Revascularization (TLR) 10.9% 10.4% 0.7189
Target Lesion Failure (TLF) 18.1% 15.3% 0.0897
Early ST (def./prob.) 0-30 days 0.76% 0.37% 0.1893
Late ST (def./prob.) 31-365 days 0.32% 0.51% 0.7555
Very late ST (def./prob.) 1-2 year 0.17% 0.13% 0.5624
Very late ST (def./prob.) 2-3 year 0.37% 0.13% 0.2268
Very late ST (def./prob.) 3-4 year 0.57% 0.20% 0.1402
Overall ST(def./prob.) 0-4 years 2.38% 1.44% 0.1333
TLF: composite of cardiac death, MI attributed to target vessel, and TLRConclusions: In this large, multicenter, real-world study, low clinical event rates at 1
year were sustained through 4 years. Although the rates of clinical outcomes in AMI
patients were slightly higher than those in non-AMI patients, the rates remained low in
both groups. A stent design that combines thin struts, a durable ﬂuoropolymer and
optimal drug dose likely underlies low long term event rates, even in thrombotic lesions.B12 JACC Vol 64/11/Suppl B jTCT-40
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Background: C-reactive protein is an important inﬂammatory marker even in acute
phase. Limited date are available whether high-sensitivity C-reactive protein (hs-CRP)
on admission predicts long-term clinical outcome depending on clinical presentation
deﬁned as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment
elevation myocardial infarction (NSTEMI).
Methods:Weenrolled consecutive 3,962 acutemyocardial infarction (AMI) patientswho
underwent percutaneous coronary intervention (PCI) in the COREA-AMI (COnvergent
REgistry of cAtholic and chonnAm university for AMI) from January 2004 to December
2009.Theprimaryendpointwas a composite of all-causedeath, anymyocardial infarction,
and any revascularization. Cut-off level of initial hs-CRP was 10 mg/L.
Results: Median follow up duration was 38.3 months (interquartile range 22.8 to
55.9months). Elevated hs-CRP was observed in 1,439 patients (36.3%). The rate of
primary endpoint was higher in high hs-CRP group (37.5% vs. 25.8%; 540 events vs.
652 events, P< 0.001). In multivariable Cox proportional hazards regression, high hs-
CRP level is independent predictor of primary endpoint (hazard ratio (HR) 1.20, 95%
conﬁdence interval (CI) 1.06-1.36, P¼0.003). In subgroup analysis, higher hs-CRP
level is associated with long-term clinical outcome in STEMI, but not in NSTEMI
(HR 1.29, 95% CI 1.10-1.52, P¼0.002. vs. HR 1.13, 95% CI 0.94-1.37, P¼0.20;
Interaction P¼0.023).Conclusions: Hs-CRP level on admission over than 10 mg/L is independent predictor
for long-term clinical outcome in patients with STEMI, but not in patients with
NSTEMI.
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Background: Mortality after percutaneous coronary intervention (PCI) is considered
as a surrogate marker for the quality of care in interventional cardiology. But mortality
after PCI may be related to multiple factors. We examine the frequencies and the
causes of mortality after PCI in the contemporary practice.
Methods: Royal Columbian Hospital is the tertiary regional cardiac centre of Fraser
Health Region in British Columbia that has a population of 1.9 million, and it provides
24/7 primary STEMI revascularization service for the region. Patients’ demographics
and procedural data are prospectively recorded in the provincial catheterization
database, which is linked to the vital statistics. The cause of death was reviewed
independently by 2 interventional cardiologists through chart review, and was clas-
siﬁed into 3 categories: (1) PCI-related, (2) non-PCI-related cardiac death, and (3)
non-cardiac death. Patients who died suddenly or out-of-the-hospital were all pre-
sumed to have PCI-related death due to stent thrombosis, unless proven otherwise.
Results: From 06/2011 to 12/2013, 6,041 PCI procedures were performed, and 1,847
(31%) cases were done during acute STEMI. A total of 154 (2.5%) patients diedSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
